Fig. 6: Robust T cell immunity against uORF-derived peptides in healthy donors. | Nature Communications

Fig. 6: Robust T cell immunity against uORF-derived peptides in healthy donors.

From: Upstream open reading frame translation enhances immunogenic peptide presentation in mitotically arrested cancer cells

Fig. 6: Robust T cell immunity against uORF-derived peptides in healthy donors.The alternative text for this image may have been generated using AI.

a Representative ELISPOT of PBMCs from two healthy donors stimulated with the uORF-derived peptide REMFIWAVA, with DMSO as the negative control. b, ELISPOT quantification from panel (a). Data were presented as spot-forming units (SFU) per 10⁶ PBMCs and represent mean ± SD from technical replicates (n = 3 for DMSO treatment or n = 4 for peptide treatment). SI stimulation index. c IFN-γ and TNF-α expression in CD8⁺ cells from two healthy donors treated with DMSO or the uORF-derived peptide REMFIWAVA. d Representative ELISPOT showing PBMCs from a single healthy donor stimulated with the uORF-derived peptide CSKVSSEY and compared against a DMSO negative control. e Quantification of the ELISPOT results displayed in (d). Data were expressed as spot-forming units (SFU) per 10⁶ PBMCs, presented as the mean ± SD from technical replicates (n = 3 for DMSO; n = 4 for the peptide). SI refers to the stimulation index. f Expression of IFN-γ and TNF-α in CD8⁺ T cells from the same single donor after treatment with DMSO or the uORF-derived peptide CSKVSSEY.

Back to article page